洞察
Insights From Our Experts
Articles
German and United Kingdom Physicians Express Frustration with Health System Challenges
This brief by Health Strategies Insights summarizes preliminary results compiled from twelve 30-minute, one-on-one, in-depth, telephone interviews with a mix of physician specialists from the United Kingdom (U.K.) and Germany. While the physicians discussed benefits of…
Innovative Therapies Call for an Integrated Drug Safety and Compliance Model
In this article, Herbert Lee, PharmD, Senior Vice President, Medical Communications and Pharmacovigilance, makes the case for an integrated approach to ensuring the safe and effective use of medications by patients. From emerging therapies to innovative…
Navigating Channel Distribution in a New (and more complex) Biopharma World
Every twist and turn in the bench-to-bedside commercialization journey introduces increasing regulatory complexity, product-specific special handling requirements, and evolving industry guidelines. With more than 300 client case studies to draw from, we’ve found three opportunities (or…
Are We Transforming In The Right Way?
Why Product Launches Can’t Be Distracted By Empty Promises. We can all agree that innovations in therapeutic development have advanced beyond traditional product launch strategies and service models. In every step of the product lifecycle, we…
Pushing Your Frontline Into A New Frontier
The pharmaceutical industry is complex. A litany of companies and brands are competing for top-of-mind usage with clinicians, a cohesive partnership with payers, and active engagement with patients. It’s hard enough to bring a drug to…
340B Drug Pricing: Challenges and Best Practices
Enacted in 1992, the 340B Drug Pricing Program was intended to stretch scarce federal resources and services to more eligible patients. Despite achieving this goal in many respects, it has also become notoriously difficult to…
Pharmaceutical Contracting from Volume to Value
Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…
Gene Therapy for Rare Disorders
With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?
Insights from AMCP 2019
EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and…
Sell’N Gene Therapies: A Landscape Assessment Of Cell And Gene Therapy Reimbursement
Cell and gene therapies hold great life-saving potential, with the ability to treat disease states with significant morbidity, mortality, or treatment-related complications. Kymriah became the first CAR-T cell therapy to bring transformative efficacy to B-cell acute…